Accentia at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh rated Accentia Biopharmaceuticals Inc. at a buy on the expanded agreement with the Mayo Clinic that prevents SinuNase competition from being used in the over-the-counter (OTC) market. Accentia may also capitalize on revenue streams from both the non-prescription and prescription chronic sinusitis (CRS) markets. According to the analyst, the amended agreement includes worldwide rights for all non-prescription (OTC, homeopathic, beauty aid) intranasal formulations to treat CRS symptoms by suppressing mucal fungi. Shares of the Tampa, Fla.-based biopharmaceutical company were down 12 cents, or 3.93%, at $2.93, on volume of 75,705 shares versus the three-month running average of 27,366 shares. (Nasdaq: ABPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.